Cargando…
High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI – The Tamip Study
BACKGROUND: Primary percutaneous coronary intervention (PCI) has been shown to be an effective therapy for patients with acute myocardial infarction (MI). Glycoprotein (GP) IIb/IIIa receptor blockers reduce thrombotic complications in patients undergoing PCI. Most available data relate to Reopro, wh...
Autor principal: | Balghith, Mohammed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503360/ https://www.ncbi.nlm.nih.gov/pubmed/23181175 http://dx.doi.org/10.4103/1995-705X.102145 |
Ejemplares similares
-
Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI
por: Türker, Yasin
Publicado: (2016) -
The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI
por: Kaymaz, Cihangir, et al.
Publicado: (2016) -
Relationship between the duration of ischemia and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012) -
Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012) -
Effect of prehospital treatment in STEMI patients undergoing primary PCI
por: Fabris, Enrico, et al.
Publicado: (2022)